Trophos
Encyclopedia
Trophos is a biopharmaceutical company specialising in the discovery and development of novel therapeutics to treat both orphan neurodegenerative diseases and more prevalent disorders.
Trophos' lead compound is TRO19622 / olesoxime
, which is now in a phase 3 trial (MitoTarget Project) in Europe in amyotrophic lateral sclerosis
. Olesoxime is a mitochondrial targeted compound, which will be established as first of a new class of therapeutic agents aimed at bringing significant therapeutic benefit to patients suffering from devastating neurological diseases.
Trophos recently also initiated the clinical development for TRO40303, a mitochondria pore modulator, which may become the first treatment to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen post myocardial infarction (MI). Pre-clinical results suggested that TRO40303 can significantly reduce infarct size following cardiac ischemia-reperfusion. The first-in-human study will enroll healthy volunteers and will compare the safety and tolerability of a single dose of TRO40303 to placebo.
Trophos' lead compound is TRO19622 / olesoxime
Olesoxime
Olesoxime is the lead compound of Trophos' proprietary cholesterol-oxime compound family of mitochondrial pore modulators. It is a molecule that has a cholesterol-like structure and displays strong neuroprotective properties...
, which is now in a phase 3 trial (MitoTarget Project) in Europe in amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis , also referred to as Lou Gehrig's disease, is a form of motor neuron disease caused by the degeneration of upper and lower neurons, located in the ventral horn of the spinal cord and the cortical neurons that provide their efferent input...
. Olesoxime is a mitochondrial targeted compound, which will be established as first of a new class of therapeutic agents aimed at bringing significant therapeutic benefit to patients suffering from devastating neurological diseases.
Trophos recently also initiated the clinical development for TRO40303, a mitochondria pore modulator, which may become the first treatment to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen post myocardial infarction (MI). Pre-clinical results suggested that TRO40303 can significantly reduce infarct size following cardiac ischemia-reperfusion. The first-in-human study will enroll healthy volunteers and will compare the safety and tolerability of a single dose of TRO40303 to placebo.